Akèy › BPCO
Etid klinik pou BPCO ap rekrite nan Etazini
97 etid pou BPCO ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Philadelphia, PA22 etid
- Miami, FL18 etid
- Birmingham, AL17 etid
- Boston, MA17 etid
- Houston, TX15 etid
- Orlando, FL15 etid
- Chicago, IL14 etid
- Baltimore, MD13 etid
- Dallas, TX12 etid
- Pittsburgh, PA12 etid
- New York City, NY11 etid
- Winston-Salem, NC9 etid
- Charlotte, NC9 etid
- Kansas City, KS9 etid
- Phoenix, AZ9 etid
- Los Angeles, CA9 etid
- Ann Arbor, MI9 etid
- Hialeah, FL8 etid
- Newport Beach, CA8 etid
- Cleveland, OH8 etid
- Detroit, MI8 etid
- Durham, NC7 etid
- Columbus, OH7 etid
- Tampa, FL7 etid
- Denver, CO7 etid
- Kendall, FL7 etid
- Milwaukee, WI7 etid
- West Palm Beach, FL6 etid
- Nashville, TN6 etid
- Aurora, CO6 etid
- Indianapolis, IN6 etid
- Knoxville, TN5 etid
- Las Vegas, NV5 etid
- Minneapolis, MN5 etid
- Ocala, FL5 etid
- Baton Rouge, LA5 etid
- Savannah, GA5 etid
- Rapid City, SD5 etid
- Farmington Hills, MI5 etid
- Atlanta, GA5 etid
Pa eta
- Alabama21 etid
- Arizona16 etid
- Colorado15 etid
- Connecticut3 etid
- Florid28 etid
- Georgia12 etid
- Idaho4 etid
- Illinois19 etid
- Indiana10 etid
- Iowa6 etid
- Kalifòni26 etid
- Kansas12 etid
- Kentucky5 etid
- Lwizyàn9 etid
- Main3 etid
- Maryland15 etid
- Massachusetts25 etid
- Michigan21 etid
- Minnesota11 etid
- Mississippi3 etid
- Missouri7 etid
- Montana3 etid
- Nebraska5 etid
- Nevada8 etid
- New Jersey7 etid
- New York19 etid
- North Carolina22 etid
- Ohio16 etid
- Oklahoma8 etid
- Oregon6 etid
- Pennsylvania32 etid
- South Carolina14 etid
- South Dakota6 etid
- Tennessee14 etid
- Texas25 etid
- Utah5 etid
- Vermont5 etid
- Virginia12 etid
- Washington5 etid
- West Virginia5 etid
- Wisconsin8 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
Ap rekriteFaz 2
Laj 40 a 85 · Tout sèks · Mizajou Sep 30, 2026 · NCT07684820Mindful Steps 2.0: Promoting Physical Activity in Patients With COPD and HF
Ap rekrite
Laj 40 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT05934565A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
Ap rekriteFaz 2
Laj 40 a 80 · Tout sèks · Mizajou Sep 25, 2026 · NCT07725939A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Sep 25, 2026 · NCT07780656A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Ap rekriteFaz 2
Laj 40 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT07759245: Vascular Function in Health and Disease
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT02966665A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
Ap rekriteFaz 4
Laj 40 a 85 · Tout sèks · Mizajou Sep 22, 2026 · NCT07053423Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Sep 22, 2026 · NCT07190209A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Sep 21, 2026 · NCT07793409An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
Ap rekrite
Laj 40 a 80 · Tout sèks · Mizajou Sep 17, 2026 · NCT06035120A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
Ap rekriteFaz 2
Laj 40 a 80 · Tout sèks · Mizajou Sep 15, 2026 · NCT07646587Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Sep 15, 2026 · NCT07190222Nebulizer Versus Handheld Maintenance Therapy for Patients With COPD
Ap rekriteFaz 4
Laj 60 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07816835A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Ap rekriteFaz 2
Laj 40 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07082738A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Sep 9, 2026 · NCT07780669Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
Ap rekriteFaz 2
Laj 40 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07059091A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Sep 3, 2026 · NCT06883305A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Sep 3, 2026 · NCT06878261A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT06603246COPD Exacerbation Follow Up
Ap rekriteEtid obsèvasyon
Laj 40 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT07118306The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
Ap rekriteEtid obsèvasyon
Laj 40 ak plis · Tout sèks · Mizajou Sep 1, 2026 · NCT07612878A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
Ap rekriteFaz 2/3
Laj 35 a 80 · Tout sèks · Mizajou Aug 31, 2026 · NCT07363694Inter-lobar Fissure Completion in Patients With Failed Bronchoscopic Lung Volume Reduction
Ap rekrite
Laj 40 a 75 · Tout sèks · Mizajou Aug 28, 2026 · NCT05257681Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia
Ap rekriteFaz 2
Laj 40 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT07037836Rademikibart IV for Acute Asthma and COPD Exacerbation
Ap rekriteFaz 2
Laj 18 a 85 · Tout sèks · Mizajou Aug 27, 2026 · NCT07705737Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.